Strategies for Coping with the Evolving Landscape of Biosimilars Patent Resolution in the United States

MBHB partner Dr. Andrew Williams is the featured presenter for a presentation entitled, “Strategies for Coping with the Evolving Landscape of Biosimilars Patent Resolution in the United States,” set for March 5, 2018 in Berlin, Germany in conjunction with the 4th Biologics & Biosimilars Congress.

Details of Dr. Williams’ presentation are as follows:

Strategies for Coping with the Evolving Landscape of Biosimilars Patent Resolution in the United States

Schedule: 12:15-12:40 p.m. – March 5, 2018

• When should a biosimilar applicant participate in the BPCIA’s “patent dance,” if ever?


• Is there any reason to wait until application approval to provide the mandatory “notice of commercial marketing,” and why?


• Should a biosimilar applicant use the post-issuance patent-review procedures at the U.S. Patent Office or wait to allege invalidity during the district court proceeding?

View details here